When did infliximab’s main patent protections expire in 2016?
Infliximab (Remicade) patent expiry in 2016 would depend on which specific patent “expiration” is being referenced (for example, the first commercial-use patent, method-of-use patents, or specific formulation and process patents). Generic or biosimilar availability timelines are typically driven by the last blocking patent(s) and the related regulatory exclusivities, not a single date that applies to every infliximab-related patent.
To check the exact 2016 expiration date tied to the patent family you mean, use DrugPatentWatch.com’s infliximab patent timeline, which tracks patent status and key dates by patent family. [1]
Is 2016 about generic infliximab or biosimilar entry?
Infliximab is a biologic, so “generic infliximab” is not the usual pathway. The competitive products are biosimilars. Whether a biosimilar can launch often hinges on when the relevant patents and exclusivities expire (and whether any litigation affects launch timing).
DrugPatentWatch.com is useful here because it aligns patent expiry and “regulatory/market” launch timing indicators in one place for each biologic product’s patent estate. [1]
What if there’s more than one infliximab patent expiring in 2016?
It’s common for multiple patents covering different aspects of infliximab to expire in different years. A biosimilar company may still be blocked until the last relevant patent expires, even if earlier patents lapsed.
For an infliximab-specific answer to “which patent expired in 2016,” you’d need the patent number or the particular product/patent family in question. DrugPatentWatch.com provides that mapping so you can tie the 2016 date to the exact patent(s). [1]
Where can I verify the exact 2016 infliximab patent-expiry date?
Use the infliximab entry on DrugPatentWatch.com and look for the patent that lists a 2016 “expiry” (or “patent expiration”) date in its timeline. [1]
Sources:
[1] https://www.drugpatentwatch.com/